Living Well With Brain Cancer: A Group-Based Intervention

This study, called "Living Well With Brain Cancer," is testing a new group self-management program for people diagnosed with brain cancer. The program involves eight virtual 90-minute sessions over 3-4 months, designed to help improve mental and behavioral health. Some participants will receive these group sessions, while others will receive educational materials online. The study wants to see if the group program is practical to offer and if it improves well-being more than just receiving educational materials. You may be able to join if you are 18 or older, live in the U.S., and have a confirmed diagnosis of a malignant brain tumor (WHO grades II, III, or IV). The study plans to enroll 64 participants, but its current status is unclear.

Study design: This interventional study plans to enroll 64 participants. It compares a group self-management program to educational materials only.
What's involved: If you join, you would participate in eight 90-minute virtual sessions over 3-4 months, or access online educational materials. Your well-being will be assessed at the start, immediately after the intervention, and 3 months later.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for 3 months after the intervention ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being

Not Yet Recruiting

NAAges 18+InterventionalSupportive care

University of Colorado, Denver

~64 participants

Updated 2026-06-05 on ClinicalTrials.gov

What's tested:Group Self-Management SessionsEducational Materials Only

At a glance

Recruiting sites

0 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change from Baseline of Overall Score from the RAND 36-Item Short Form Survey Instrument (SF-36)

Measured over Baseline, immediately post-intervention, and 3 months post-intervention

Conditions

Brain Cancer

Where it's being run

2 sites across 2 states

Colorado1

Ohio1

Study leadership

Bethany M Kwan, PhD, MSPH · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Who to contact

Research Services Professional

[email protected]

303-724-1723

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Currently living in the United States

Aged 18 years or older

Confirmed diagnosis of a malignant brain tumor including diffuse gliomas, World Health Organization (WHO) grades II, III, and IV (either by directly sharing their pathology report or confirmation from their prescribing treating provider)

Treating prescribing provider who follows regularly with participant

Exclusion

\<1 month since initial diagnosis and/or \<1 month since surgical resection

Enrollment in hospice

Significant physical or cognitive disabilities that prohibit involvement using our clinician's judgement as a self-management expert, with consultation with personal clinician if needed

Currently receiving psychiatric treatment for a serious mental illness (e.g., schizophrenia)

Not able to communicate in English at a conversational level

What this trial measures

Change from Baseline of Overall Score from the RAND 36-Item Short Form Survey Instrument (SF-36)Baseline, immediately post-intervention, and 3 months post-intervention
Evaluated by the change overall score of the RAND 36-Item Short Form Survey Instrument (SF-36) at baseline, immediate after intervention, and 3 months post-intervention

Trialytics